DATA GRAPHICS | Data Byte
Assessing market performance after a preclinical IPO
Criticism of the preclinical IPO class not borne out by the numbers
October 26, 2022 12:10 AM UTC
Preclinical IPOs are often criticized for their high-risk nature, but so far, the share prices of preclinical companies that went public in 2017-20 have performed as well as their peers with clinical or marketed assets.
The distribution and median change in share price was similar during the four-year period across the two groups, with the bulk in both cases under water from their IPO price...
BCIQ Company Profiles